Inhibition of store-operated calcium channels by N-arachidonoyl glycine (NAGly): no evidence for the involvement of lipid-sensing G protein coupled receptors

Aykut Deveci1, Jessy Hasna1 & Alexandre Bouron1,2*

N-arachidonoyl glycine (NAGly) is an endogenous lipid deriving from the endocannabinoid anandamide (AEA). Identified as a ligand of several G-protein coupled receptors (GPCRs), it can however exert biological responses independently of GPCRs. NAGly was recently shown to depress store-operated Ca2+ entry (SOCE) but its mechanism of action remains elusive. The major aim of this study was to gain a better knowledge on the NAGly-dependent impairment of SOCE in neurons of the central nervous system (CNS) from mice. First, we examined the expression of genes encoding for putative lipid sensing GPCRs using transcriptomic data publicly available. This analysis showed that the most abundant GPCRs transcripts present in the cerebral cortices of embryonic brains were coding for lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) receptors. Next, the presence of functional receptors was assessed with live-cell calcium imaging experiments. In primary cortical cells S1P and LPA mobilize Ca2+ from internal stores via a mechanism sensitive to the S1P and LPA receptor antagonists Ex26, H2L5186303, or Ki16425. However, none of these compounds prevented or attenuated the NAGly-dependent impairment of SOCE. We found no evidence for the requirement of lipid sensing GPCRs in this inhibitory process, indicating that NAGly is an endogenous modulator interfering with the core machinery of SOCE. Moreover, these data also raise the intriguing possibility that the depression of SOCE could play a role in the central effects of NAGly.
SOCE is an important physiological Ca\(^{2+}\) route of the plasma membrane. It is activated in response to the depletion of the ER Ca\(^{2+}\) stores and involves distinct actors: stromal interacting molecules (STIM1–2) and Orai-1–3 channels\(^{16,18}\). STIM1 are ER resident proteins that seem to function as Ca\(^{2+}\) sensors\(^\text{17}\). The depletion of the ER Ca\(^{2+}\) stores governs the molecular interaction between STIM and plasma membrane Ca\(^{2+}\) channels of Orai type that are responsible for the SOCE response\(^\text{17,18}\). Recent studies identified NAGly as a potent inhibitor of SOCE in various cell lines (NIH-3T3 fibroblasts, human endothelial cell line EA.hy926, rat pancreatic β-cell line INS-1 832/13, rat basophilic leukemia cell line RBL-2H3) and in primary cultured neural cells\(^\text{5,20,21}\). Two hypotheses were put forward to explain the NAGly-dependent depression of SOCE\(^\text{20}\): (1) direct disruption of the coupling between STIM and Orai, or (2) recruitment of an intracellular signalling cascade activated downstream to NAGly-sensitive receptors and regulating negatively SOCE activity. The aim of the present work was to verify whether a lipid sensing GPCR is contributing to the NAGly-induced impairment of SOCE in cortical neurons. First, we analyzed a recent publicly available transcriptomic dataset obtained by RNAssequenc\(^\text{22}\) to characterize the expression of genes encoding for putative lipid sensingGPCRs in the cerebral cortices of embryonic mice. The most abundant transcripts were coding for lysophosphatidic acid (LPA) and sphingosine-1 phosphate (SIP) receptors. After having checked the presence of functional receptors, the contribution of LPA and SIP receptors to the NAGly-dependent inhibition of SOCE was evaluated using a pharmacological approach.

**Material and Methods**

**Animal and ethical statement.** C57BL6/J (stock #000664) mice were obtained from the Jackson Laboratory (USA). They were housed in a temperature-controlled room under a 12 h light–12 h dark cycle with ad libitum access to food and water. An environmental enrichment consisting in the addition of tunnels was provided for all animals in accordance with the Animal Welfare Committee of the CEA Grenoble. Experimental procedures were approved by the animal care committee of the CEAs Life Sciences Division (CETEA, A14-006). Experiments were conducted in compliance with the French legislation and the European Community Directive of 24 November 1986 (86/609/EEC).

**Primary cultures of cortical neurons.** Cells were dissociated from cerebral cortices collected from embryonic (E13) mice (with the vaginal plug as E0) according to\(^\text{12,24}\). Briefly, tissues were placed in a 1.5 mL Eppendorf tube containing 1 mL of an ice-cold Ca\(^{2+}\)- and Mg\(^{2+}\)-free Hank’s solution supplemented with 33 mM glucose, 4.2 mM NaHCO\(_3\), 10 mM HEPES, and 1% penicillin/streptomycin. Cells were isolated by a mechanical trituration in vitro.

**Calcium imaging experiments with Fluo-4.** The culture medium was removed and replaced by a saline containing (in mM) 150 NaCl, 5 KCl, 1 MgCl\(_2\), 2 CaCl\(_2\), 5.5 glucose, 10 HEPES (pH 7.4, NaOH). LPA- and SIP-induced Ca\(^{2+}\) responses were analyzed with Fluo-4. Cells were incubated with 5 µM Fluo-4/AM for 20 min following procedures described previously\(^\text{23,24}\). Images were obtained by a CCD CoolSnap HQ2 camera (Princeton Instruments, Roper Scientific, France) mounted on an inverted Zeiss A1 microscope (Carl Zeiss, France). Cells were excited at 470 nm and emission was collected at 525 nm using a DG-4 wavelength switcher (Princeton Instruments, Roper Scientific, France). MetaFluor (Universal Imaging, Roper Scientific, France) was used for image acquisition and analysis. All experimental procedures were conducted at room temperature. Time-lapse changes in Fluo-4 fluorescence intensity were collected at a frequency of 0.2 Hz from 30–45 cell bodies per dish and analyzed off-line by defining regions of measurements. Results were expressed as F/F0, with F being the fluorescence at each time point and F0 being the mean baseline fluorescence that was monitored at the end of the recording and never re-used. A positive LPA (or SIP)-induced calcium response was determined as one F/F0 greater than 0.02 that develops within 50 s upon the application of the agonist. Fluo-4 responses were measured as area under curve (AUC).

**Calcium imaging experiments with Fura-2.** The fluorescent Ca\(^{2+}\) probe Fura-2 was used to study store-operated Ca\(^{2+}\) entry (SOCE). The experimental conditions and setup were as above except that cells were incubated with 2.5 µM Fura-2 for 20 min at room temperature. They were then washed twice and kept in a Fura-2-free saline solution for >12 min at room temperature. A dual excitation at 340 and 380 nm was used and emission was collected at 515 nm. Images were acquired at 0.2 Hz and analyzed off-line. The classical “Ca\(^{2+}\) add-back” protocol was used to study SOCE. Cells were bathed in a nominally Ca\(^{2+}\)-free saline containing (in mM) 150 NaCl, 5 KCl, 3 MgCl\(_2\), 5.5 glucose, 10 HEPES (pH 7.4, NaOH). SOCE activation was triggered by depletion of the ER Ca\(^{2+}\) pool with 200 nM thapsigargin, which induced a transient elevation in intracellular Ca\(^{2+}\) concentration before re-admission of 2 mM external Ca\(^{2+}\). SOCE responses were analyzed in cells generating a rapid Ca\(^{2+}\) rise upon the application of a depolarizing saline containing 90 mM KCl. In cultures of embryonic cortical cells, KCl responding cells are identified as neurons whereas KCl-unresponsive cells are considered as non-neuronal cells\(^\text{25}\). The depolarizing (K\(^{+}\)-rich) medium had the following composition (in mM): 65 NaCl, 90 KCl, 1 MgCl\(_2\), 2 CaCl\(_2\), 5.5 glucose, 10 HEPES (pH 7.4, NaOH). Ca\(^{2+}\) changes as a function of time were expressed as delta ratio F340/F380 whereas total Ca\(^{2+}\) responses were measured as area under curve (AUC).

Stock solutions of Ex26, Ki16425, and BTP2 were prepared in dimethyl sulfoxide (DMSO). Methanol and ethanol were used for preparing stock solutions of SIP and NAGly, respectively. These stock solutions were diluted at least 1000-fold into the recording saline immediately before use so that the final concentration of vehicle never
exceeded 0.1%. Control experiments were performed with DMSO, ethanol and methanol alone. None of the solvent altered cytosolic Ca\(^{2+}\) signals, at least at the concentrations used.

**Analysis of gene expression by RNaseq.** The RNAseq gene expression data derive from\(^\text{22}\). Raw fastq files are publicly available and can be found on the GEO repository under accession number: GSEXXX.

**Data and Statistical analysis.** Each experimental condition as well as its appropriate control were tested on the same batch of primary neuronal cell cultures. For the Ca\(^{2+}\) imaging experiments, all experiments were done \(\geq 3\) times (e.g. with \(\geq 3\) distinct biological samples) using distinct dishes from different batches of cells (e.g. from distinct pregnant mice). Data are presented as means ± standard error of the mean (SEM) with \(n\) being the number of biological replicates. SigmaPlot (version 10.0, Systat Software) and SigmaStat (version 3.5, Systat Software) were used for plotting graphs and statistical analysis, respectively. Differences between several groups of cells were tested using one-way analysis of variance (ANOVA) followed by a Bonferroni’s post hoc test. A \(P\) value < 0.05 was considered statistically significant.

**Materials.** Fluo-4/AM, Fura-2 and tissue culture media were from Molecular Probes (Invitrogen, France). N-arachidonoyl glycine (NAGly) was from Tocris (Bio-Technie, France). All the other reagents were obtained from Sigma-Aldrich (France).

**Results**

**mRNA expression of lipid sensing GPCRs in the cerebral cortex of embryonic mice.** In order to determine whether NAGly is acting via a GPCR, we analyzed the expression of genes encoding for putative lipid sensing GPCRs in the embryonic cerebral cortex. Table 1 provides the list of the 60 mouse genes selected\(^\text{26–30}\). The transcriptomic data were extracted from a recent RNAseq study\(^\text{22}\). The expression pattern of putative lipid sensing GPCRs was analyzed at 3 embryonic ages: E11, E13 and E17. Only genes for which the number of transcripts per million (TPM) was \(>2\) were considered as significantly expressed\(^\text{31}\), therefore when the number of transcripts was \(<2\) TPM, the gene was eliminated from the analysis. This resulted in the selection of 14 genes encoding for putative lipid sensing GPCRs (Fig. 1). In this RNAseq analysis the genes encoding for GPR18, GPR55 and GPR92, 3 putative targets of NAGly, were not expressed. Overall, the most abundant transcripts were coding for cannabinoid receptors type 1 (CB₁) (Cnr1 gene), the orphan receptor GPR12, lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) receptors (Fig. 1). Of note, the abundance of CB₁ and GPR12 transcripts increased markedly during the embryonic development of the cerebral cortex whereas the expression of genes encoding for LPA and S1P receptors was repressed. Since all the live-cell Ca\(^{2+}\) imaging reported previously were conducted on cortical islands isolated from E13 brain cortical cortices\(^\text{8}\) we focused our attention on the most expressed lipid sensing GPCR genes at that embryonic age: S1pr1, Lpar2 and Lpar6 (vertical arrows, Fig. 1). They encode for S1P₁, LPA2 and LPA6 receptors, respectively. CB₁ was excluded from our analysis because NAGly has no affinity for CB₁ receptors\(^\text{32}\) and the CB₂ antagonist AM251 did not prevent the NAGly-induced responses in cortical neurons\(^\text{9}\), arguing against a role for these receptors. On the other hand, GPR12 was also not considered as a likely target of NAGly because the GPR12 gene was weakly expressed at E13 (Fig. 1). Its expression was strongly upregulated but only at the end of corticogenesis (E17).

**Presence of functional LPA and S1P receptors.** The activation of S1P and LPA receptors mobilizes Ca\(^{2+}\) internal stores\(^\text{33–36}\). We thus performed live-cell Ca\(^{2+}\) imaging fluorescent microscopy experiments with Fluo-4 to assess the presence of functional S1P and LPA receptors. Several cell populations are present in the primary cultures. For instance, 80–85% of the cells express βIII-tubulin (a marker of post-mitotic neurons) and possess voltage-gated Ca\(^{2+}\) channels\(^\text{37,38}\), indicating that most cells display a post-mitotic neuronal phenotype. First, the presence of functional LPA and S1P receptors was assessed in the entire cell population. LPA (10 μM, Fig. 2A) and S1P (10 μM, Fig. 2C) evoked prominent Ca\(^{2+}\) rises in ~15% (61/416 cells) and ~13% (39 of 303) of the cells tested, respectively. The LPA-induced Ca\(^{2+}\) signals were partially blocked by 10 μM H2L5186303, a selective LPA\(_{2,3}\) receptor antagonist\(^\text{39}\), and nearly completely suppressed by 10 μM Ki16425, a LPA\(_{1,2,3}\) receptor antagonist\(^\text{39–41}\) (Fig. 2B). The percentage of cells responding to LPA was 12% (29/238 cells) and <1% (1/169 cells) with H2L5186303 and Ki16425, respectively. Therefore, H2L5186303 diminished the peak of the Ca\(^{2+}\) rise without affecting the number of LPA responsive cells whereas Ki16425 affected both parameters. The S1P₁ receptor antagonist Ex26 (1 μM)\(^\text{40}\) reduced the peak amplitude of the S1P-induced Ca\(^{2+}\) signals and diminished the number of responsive cells with only 12 cells out 220 tested (~5%) generating a Ca\(^{2+}\) signal in response to 10 μM S1P (Fig. 2D). In each instance, depleting the ER with thapsigargin prevented the development of a Ca\(^{2+}\) rise upon LPA or S1P application (Fig. 2B, D).

Previous reports showed that LPA and S1P receptors are mainly found in proliferative regions of the immature cerebral cortex, with few post-mitotic neurons responding to LPA and S1P\(^\text{30}\). This latter point was checked by using a depolarizing saline solution containing 90 mM KCl to evoke KCl-dependent Ca\(^{2+}\) rises. Acutely cultured cells were undifferentiated cells. When cultured for several days, some of these differentiate into neurons (post-mitotic) responding to high-K⁺ whereas non-differentiated cells are not high-K⁺ sensitive. In cultures of embryonic cortical cells, KCl responding cells are identified as neurons whereas KCl-unresonsing cells are considered as non-neuronal cells\(^\text{25}\). Overall, only 10 of 67 LPA sensitive cells (~15%) generated an intracellular Ca\(^{2+}\) rise in response to KCl. These data are consistent with a previous report showing that in the embryonic cerebral cortex LPA receptors are predominantly expressed by neural precursor cells with only a small minority of neurons responding to LPA\(^\text{30}\). On the other hand, 5 of 25 S1P sensitive cells (20%) were KCl-responsive cells. This indicates that the S1P-sensitive cells are also mainly found in KCl-insensitive cells\(^\text{31}\). Taken together, LPA or S1P mobilizes Ca\(^{2+}\) from the ER in a subset of cells (<20%). These functional LPA- and S1P-sensitive receptors are essentially expressed by non-neuronal cells\(^\text{43,44}\).
| EnsemblID       | Gene name      | other names            | Gene description                          |
|-----------------|----------------|------------------------|-------------------------------------------|
| ENSMUSG00000004288 | Cnr1           | cannabinoid receptor 1 |                                           |
| ENSMUSG000000062585 | Cnr2           | cannabinoid receptor 2 |                                           |
| ENSMUSG000000046856 | Gpr1           | G protein-coupled receptor 1 |                                           |
| ENSMUSG000000046856 | Gpr1           | G protein-coupled receptor 1 |                                           |
| ENSMUSG000000044417 | Gpr4           | G protein-coupled receptor 4 |                                           |
| ENSMUSG000000046922 | Gpr6           | G protein-coupled receptor 6 |                                           |
| ENSMUSG000000041468 | Gpr12          | G protein-coupled receptor 12 |                                          |
| ENSMUSG000000052229 | Gpr17          | G protein-coupled receptor |                                           |
| ENSMUSG000000050350 | Gpr18          | G protein-coupled receptor 18 |                                          |
| ENSMUSG000000053647 | Gpr30          | G protein-coupled estrogen receptor 1 |                                           |
| ENSMUSG000000071311 | Gpr31b         | G protein-coupled receptor 31 |                                           |
| ENSMUSG000000040229 | Gpr34          | P2Y12 | G protein-coupled receptor 34 |                                           |
| ENSMUSG000000026271 | Gpr35          | G protein-coupled receptor 35 |                                           |
| ENSMUSG000000049608 | Gpr55          | G protein-coupled receptor 55 |                                           |
| ENSMUSG000000040372 | Gpr63          | G protein-coupled receptor 63 |                                           |
| ENSMUSG000000021886 | Gpr65          | TDAG8 | G protein-coupled receptor 65 |                                           |
| ENSMUSG000000047415 | Gpr68          | OGR1 | G protein-coupled receptor 68 |                                           |
| ENSMUSG000000049241 | gpr81          | Hcar1 | hydroxocarboxylic acid receptor 1 |                                           |
| ENSMUSG000000063234 | Gpr84          | G protein-coupled receptor 84 |                                           |
| ENSMUSG000000051431 | Gpr87          | G protein-coupled receptor 87 |                                           |
| ENSMUSG000000045502 | Gpr109A        | Hcar2 | hydroxocarboxylic acid receptor 2 |                                           |
| ENSMUSG000000051209 | Gpr119         | G-protein coupled receptor 119 |                                          |
| ENSMUSG000000064272 | Gpr131         | Gpbar1 | G protein-coupled bile acid receptor 1 |                                           |
| ENSMUSG000000021298 | Gpr132         | G protein-coupled receptor 132 |                                          |
| ENSMUSG000000073008 | Gpr174         | G protein-coupled receptor 174 |                                          |
| ENSMUSG000000051212 | Gpr183         | G protein-coupled receptor 183 |                                          |
| ENSMUSG000000034730 | Adgrb1         | Bail | adhesion G protein-coupled receptor B1 |                                           |
| ENSMUSG000000046908 | Lbhr1          | leukotriene B4 receptor 1 |                                           |
| ENSMUSG000000040432 | Lbhr2          | leukotriene B4 receptor 2 |                                           |
| ENSMUSG000000052821 | Cysltr1        | cysteinyl leukotriene receptor 1 |                                          |
| ENSMUSG000000033470 | Cysltr2        | cysteinyl leukotriene receptor 2 |                                          |
| ENSMUSG000000081489 | Pigdr          | prostaglandin D receptor |                                           |
| ENSMUSG000000034117 | Pigdr2         | prostaglandin D2 receptor 2 |                                          |
| ENSMUSG000000019464 | Ptgdr1         | prostaglandin E receptor 1 |                                           |
| ENSMUSG000000037759 | Pigdr2         | prostaglandin E receptor 2 (subtype EP2) |                                          |
| ENSMUSG000000040016 | Pigdr3         | prostaglandin E receptor 3 (subtype EP3) |                                          |
| ENSMUSG000000039942 | Pigdr4         | prostaglandin E receptor 4 (subtype EP4) |                                          |
| ENSMUSG000000044453 | Ffar1          | free fatty acid receptor 1 |                                           |
| ENSMUSG000000051314 | Ffar2          | free fatty acid receptor 2 |                                           |
| ENSMUSG000000051314 | Ffar2          | free fatty acid receptor 2 |                                           |
| ENSMUSG000000054200 | Ffar4          | free fatty acid receptor 4 |                                           |
| ENSMUSG000000028036 | Ptgfr          | prostaglandin F receptor |                                           |
| ENSMUSG000000052270 | Fpr2           | formyl peptide receptor 2 |                                           |
| ENSMUSG000000043017 | Ptgir          | prostaglandin I receptor |                                           |
| ENSMUSG000000038668 | Lpar1          | lysophosphatidic acid receptor 1 |                                          |
| ENSMUSG000000031861 | Lpar2          | lysophosphatidic acid receptor 2 |                                          |
| ENSMUSG000000036832 | Lpar3          | lysophosphatidic acid receptor 3 |                                          |
| ENSMUSG000000049929 | Lpar4          | lysophosphatidic acid receptor 4 |                                          |
| ENSMUSG000000067714 | Lpar5          | lysophosphatidic acid receptor 5 |                                          |
| ENSMUSG000000033446 | Lpar6          | lysophosphatidic acid receptor 6 |                                          |
| ENSMUSG000000048419 | Gpr80          | Osgr1, Gpr99, P2Y15 | oxoglutarate (alpha-ketoglutarate) receptor 1 |                                           |
| ENSMUSG000000056529 | Pfatr          | platelet-activating factor receptor |                                          |
| ENSMUSG000000050921 | P2ry10         | purinergic receptor P2Y G-protein coupled 10 |                                          |
| ENSMUSG000000045092 | S1pr1          | sphingosine-1-phosphate receptor 1 |                                           |
| ENSMUSG000000043895 | S1pr2          | sphingosine-1-phosphate receptor 2 |                                           |
| ENSMUSG000000067586 | S1pr3          | sphingosine-1-phosphate receptor 3 |                                           |
| ENSMUSG000000044199 | S1pr4          | sphingosine-1-phosphate receptor 4 |                                          |

Continued
Ca²⁺ blocker BTP2 45,46 (1 could be detected (e.g. having TPM values encoding for putative lipid sensing GPCRs were selected (see Table 1). Transcripts of only 14 genes (out of 60) of these 14 genes at 3 embryonic ages: E11, E13 and E17. Genes that were repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3) appear on the right. Vertical arrows indicate the 3 most abundant transcripts at E13 (except Gper1, Gpr34, Adgrb1) are shown on the left whereas genes that were induced (Cnr1, Gpr4, Gpr12, Gpr17, Gper1, Gpr34, Adgrb1) are shown on the left whereas genes that were repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3) appear on the right. Vertical arrows indicate the 3 most abundant transcripts at E13 (except CB₁, see text for further details).

Before testing the contribution of LPA and S1P receptors in the NAGly-dependent alteration of SOCE, it was important to check whether the receptor antagonists Ki16425 and Ex26 could alter SOCE on their own. In the following experiments, the ratiometric Ca²⁺ probe Fura-2 was used to analyze SOCE in cells that responded to the KCl challenge (i.e. post-mitotic neurons). Cells, bathed in a nominally Ca²⁺-free medium, were challenged with thapsigargin to deplete ER Ca²⁺ stores. A subsequent re-admission of external Ca²⁺ was followed by an intracellular elevation of Ca²⁺ (open circles, Fig. 3A). This entry of Ca²⁺ was sensitive to the CRAC channel blocker BTP2 45,46 (1 µM, gray up triangles, Fig. 3A). The thapsigargin-evoked Ca²⁺ release was unaffected by Ex26 (1 µM, filled down triangles) or Ki16425 (10 µM, gray squares) (Fig. 3A). The SOCE response was however upregulated by Ki16425 but not by Ex26. This is further illustrated in Fig. 3B showing the Ca²⁺ release and entry analyzed as area under the curve for each condition tested. Ki16426 enhanced the SOCE signal by nearly 30% (n = 5, p < 0.05) (Fig. 3B, gray bar). Altogether, these data show that the LPA and S1P receptor antagonists used did not alter the ER Ca²⁺ release. The SOCE response was also unaffected by Ex26 but augmented by Ki16426. This potentiating effect was not investigated further.

NAGly depresses SOCE independently of LPA and S1P receptors. After having shown the presence of functional receptors sensitive to LPA and S1P, their involvement in the NAGly-induced impairment of SOCE was considered. In the following set of experiments, Fura-2-loaded cells were first stimulated with a K⁺-rich saline (90 mM KCl) before recording SOCE responses in neurons (i.e. in KCl-responsive cells). Figure 4A shows SOCE without NAGly (open circles) and in the presence of NAGly (10 µM, gray down triangles). As already illustrated9, NAGly exerts complex actions on neuronal Ca²⁺ signalling: (i) it induces a release of cations (Ca²⁺ and Zn²⁺) that develops prior to thapsigargin addition (phase ➀, Fig. 4A); (ii) it upregulates the thapsigargin-dependent Ca²⁺ release (phase ➁); and (iii) reduces the amplitude of SOCE (phase ➂). Even in the presence of 1 µM Ex26 (gray up triangles) or 10 µM Ki16425 (filled squares, Fig. 4A), NAGly elevated the Fura-2 fluorescence on its own (phase ➀) and potentiated the thapsigargin-evoked Ca²⁺ release (phase ➁). The NAGly-induced inhibition of SOCE (phase ➂) was also not affected by Ex26 or Ki16425 (Fig. 4A). NAGly had however no inhibitory action on the entry of Ca²⁺ when added together with BTP2 (open squares, Fig. 4A).

The Fura-2 Ca²⁺ signals (phases ➀, ➁, ➂) observed without NAGly (white bars), with NAGly (gray bars), NAGly + Ki16425 (black bars), NAGly + Ex26 (black/white bars), and NAGly + BTP2 (hatched bars) were analyzed as area under curve (AUC) (Fig. 4B). In conclusion, Ki16425 and Ex26 failed to affect the NAGly-evoked Ca²⁺ rise (phase ➀). These blockers also did not influence the potentiation of the thapsigargin-induced Ca²⁺ signal induced by NAGly (phase ➁) and the NAGly-dependent depression of SOCE (phase ➂). It is proposed that NAGly inhibits a BTP2-sensitive Ca²⁺ entry pathway without recruiting LPA or S1P-sensitive receptors.

Discussion
NAGly inhibits SOCE 20. This impairment has been observed in every cell type and cell line tested so far like fibroblasts, neurons, EA.hy926 (human endothelial cell line), INS-1 832/13 (rat pancreatic β-cell line), and RBL-2H3 cells (rat basophilic leukemia cell line) 21,22,23. However, the mechanism by which NAGly alters SOCE is unclear. In the present study we addressed the question of the contribution of lipid sensing GPCRs as targets of NAGly.

### Table 1. List of selected 60 murine genes encoding for lipid sensing G protein-coupled receptors (GPCRs).

| EnsemblID       | Gene name       | other names | Gene description                          |
|-----------------|-----------------|-------------|------------------------------------------|
| ENSMUSG00000045087 | S1pr5          |             | sphingosine-1 phosphate receptor 5       |
| ENSMUSG000000027762 | Sucnr1         |             | succinate receptor 1                     |
| ENSMUSG00000034881 | Tbx2a2r        |             | thromboxane A2 receptor                  |

**Figure 1.** mRNA expression of putative lipid sensing GPCRs in the embryonic murine cortex. The data used to plot this graph were extracted from a previous whole-genome transcriptomic analysis 22. A total of 60 genes encoding for putative lipid sensing GPCRs were selected (see Table 1). Transcripts of only 14 genes (out of 60) could be detected (e.g. having TPM values ≥ 2). The graph shows the temporal pattern of the mRNA abundance of these 14 genes at 3 embryonic ages: E11, E13 and E17. Genes that were induced (Cnr1, Gpr4, Gpr12, Gpr17, Gper1, Gpr34, Adgrb1) are shown on the left whereas genes that were repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3) appear on the right. Vertical arrows indicate the 3 most abundant transcripts at E13 (except CB₁, see text for further details).
with the aim to gain a better knowledge on neuronal SOCE functioning and regulation. To reach that goal, we took advantage of a recent transcriptomic analysis of the whole murine genome by RNA-seq\textsuperscript{22}. This allowed us to consider the mRNA expression of 60 putative lipid sensing GPCRs\textsuperscript{26–30}. Overall, transcripts of 14 genes (\textsim 25\%) were detected. Their abundance varied during embryonic development with 7 genes being induced (Cnr1, Gpr4, Gpr12, Gpr17, Gpr34, Adgrb1) and 7 genes being repressed (Lpar1, Lpar2, Lpar4, Lpar6, S1pr1, S1pr2, S1pr3). At E13, age at which cerebral cortices were collected to perform the \(\text{Ca}^{2+}\) imaging experiments\textsuperscript{9}, the most abundant mRNAs were those coding for CB\(_1\) and S1P\(_1\) receptors, followed by LPA\(_2\) and LPA\(_6\) receptors. Since the

Figure 2. Presence of functional LPA- and S1P-sensitive receptors. The presence of functional LPA and S1P receptors was verified with the fluorescent \(\text{Ca}^{2+}\) probe Fluo-4. In these experiments, cells were maintained in a nominally \(\text{Ca}^{2+}\)-free saline. Panels A and C show somatic Fluo-4 signals (F/F\(_0\)) as a function of time in response to 10 \(\mu\)M LPA (n = 10) (panel A) and 10 \(\mu\)M S1P (n = 9) (panel C). Panel B shows the LPA-induced \(\text{Ca}^{2+}\) rises measured as area under the curve (AUC) in the absence (white bar, n = 10) or presence of H2L5186303 (10 \(\mu\)M, n = 5), Ki16425 (10 \(\mu\)M, n = 7), or after the application of thapsigargin (Tg, 200 nM, n = 5). *\(p < 0.05\) vs LPA, one-way ANOVA followed by a Bonferroni’s post hoc test. Panel D shows the Fluo-4 responses (measured as area under the curve, AUC) induced by S1P alone (10 \(\mu\)M, n = 9), S1P + Ex26 (1 \(\mu\)M, n = 7), and S1P applied after thapsigargin (Tg, 200 nM, n = 5), with *\(p < 0.05\) vs S1P, one-way ANOVA followed by a Bonferroni’s post hoc test. Antagonists of LPA and S1P receptors were added 4–7 min before time 0 and remained present throughout the recordings. LPA and S1P can stimulate store-released \(\text{Ca}^{2+}\). Pre-depleting the ER \(\text{Ca}^{2+}\) with Tg prevents any response to LPA or S1P.
cannabinoid receptor CB₁ does not seem to mediate the NAGly-dependent impairment of SOCE⁹, only the contribution of S1P and LPA receptors in the NAGly-mediated modulation of SOCE was investigated.

Five subtypes of S1P receptors are known (S₁P₁–S₁P₅). They belong to the group of GPCRs and mediate most of the biological actions of the bioactive sphingolipid S₁P 3⁰. Embryonic cerebral cortices displayed a high mRNA level of S₁P₁ receptors that declined during embryonic brain development. In addition, cultured cortical cells expressed functional receptors coupled to the release of Ca²⁺ from the ER and sensitive to the S₁P₁ antagonist Ex26. These findings are in line with previous reports showing that S₁P₁ is the major S₁P receptor of the murine embryonic brain, followed by S₁P₂ and S₁P₃ receptors. It is detected as early as E14, highly expressed in proliferative regions (neurogenic ventricular zone) but its expression decreases at E16 and E18 ⁴⁷. The activation of S₁P₁ receptors is coupled to the mobilization of Ca²⁺ ⁳³.

LPA receptors constitute another important family of GPCRs sensitive to bioactive lipids ³⁰,⁴⁹. LPA signalling is of particular physiological relevance for the embryonic brain cortex ⁴⁸. At E12.5 the most abundant transcripts in the telencephalon are LPA₁, LPA₂ and LPA₄ ⁵⁰. In the present work, the main genes expressed at E13 were encoding for LPA₂ and LPA₆. It is detected as early as E14, highly expressed in proliferative regions (neurogenic ventricular zone) but its expression decreases at E16 and E18 ⁴⁷. The activation of S₁P₁ receptors is coupled to the mobilization of Ca²⁺ ³³.

After having shown the presence of functional LPA and S₁P receptors, their contribution to the NAGly-dependent depression of SOCE was evaluated. The pharmacological blockade of S₁P and LPA receptors with Ex26 or Ki16425 did not abolish or attenuate the NAGly-dependent impairment of SOCE. Some cellular responses of NAGly have been shown to be mediated by the orphan receptor GPR55 ¹¹. However, we found no evidence for the presence of significant levels of GPR55 mRNA. Furthermore, the GPR55 agonist AM251 ⁴⁹, which induces a GPR55-dependent mobilization of Ca²⁺ with an EC₅₀ of ~0.6 µM ⁵⁰, fails to evoke any Ca²⁺ release when

Figure 3. Effects of Ex26, Ki16425, and BTP2 on the thapsigargin-evoked Ca²⁺ release and SOCE. SOCE responses were analysed with Fura-2. Cells were kept in a nominally Ca²⁺-free medium. ER Ca²⁺ stores were depleted with thapsigargin (Tg, 200 nM) before re-introducing external Ca²⁺. The resulting increase in intracellular Ca²⁺ is due to Ca²⁺ entering via the plasma membrane. Panel A shows somatic Ca²⁺ responses (expressed as Δ ratio F₃₄₀/F₃₈₀) as a function of time, and generated by the sequential addition of Tg (200 nM, horizontal gray bar) followed by the readmission of 2 mM external Ca²⁺ (horizontal black bar). Four conditions are shown: without antagonists of LPA and S₁P receptors (Control, open circles, n = 7), with 1 µM Ex26 (gray triangles, n = 5), 10 µM Ki16425 (filled squares, n = 5), and with 1 µM BTP2 (symbols, n = 5). When tested, Ex26 (or Ki16425) and BTP2 were added 4–7 and 11–12 min, respectively, before time 0 and were also present during the recordings. One time point out of 3 is shown. Panel B shows the thapsigargin-evoked Ca²⁺ release and SOCE measured as area under the curve (AUC). Mean ± SEM.
applied to cortical cells at 10 μM. This further suggests that GPR55 does not participate in the NAGly-induced alteration of neuronal Ca\(^{2+}\) signalling.

In conclusion, our data show that NAGly inhibits a BTP2-sensitive Ca\(^{2+}\) entry, which is most likely a SOCE. This occurs independently of GPR55, LPA and S1P receptors (present report), and via a mechanism insensitive to the pertussis toxin\(^9\). It is worth recalling that NAGly regulates voltage-gated Ca\(^{2+}\) channel activity without acting on GPCRs\(^8,13\). Although we cannot exclude the possibility that NAGly acts on an orphan lipid sensing GPCR that was not considered in the present study, our report suggests that NAGly disturbs the coupling of the core components of the SOCE machinery (STIM-Orai)\(^20\). This inhibitory process does not seem to develop in response to an intracellular signalling cascade. These past\(^9\) and present data show that the phytocannabinoid cannabidiol, the endocannabinoid AEA and its derivative NAGly are potent inhibitors of neuronal SOCE. This indicates that NAGly and endocannabinoids are endogenous SOCE modulators, and raises the possibility that the depression of SOCE could play a role in the neuro-behavioural effects of cannabinoids and signalling lipids.

Received: 30 May 2019; Accepted: 28 January 2020; Published online: 14 February 2020

References
1. Huang, S. M. et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 276, 42639–42644, https://doi.org/10.1074/jbc.M107351200 (2001).
2. Bradshaw, H. B. et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem. 10, 14, https://doi.org/10.1186/1471-2091-10-14 (2009).
3. Barbara, G. et al. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J. Neurosci. 29, 13106–13114, https://doi.org/10.1523/JNEUROSCI.2919-09.2009 (2009).
4. Staton, P. C. et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 139, 225–236, https://doi.org/10.1016/j.pain.2008.04.006 (2008).
8. Chemin, J., Cazade, M. & Lory, P. Modulation of T-type calcium channels by bioactive lipids.

10. McHugh, D.

11. Console-Bram, L.

13. Lu, V. B., Puhl, H. L. III. & Ikeda, S. R. N-Arachidonyl glycine does not activate G protein-coupled receptor 18 signaling via

16. Parekh, A. B. Store-operated CRAC channels: function in health and disease.

24. Chauvet, S.

25. Gruszczynska-Biegala, J., Sladowska, M. & Kuznicki, J. AMPA Receptors Are Involved in Store-Operated Calcium Entry and

31. Wagner, G. P., Kin, K. & Lynch, V. J. A model based criterion for gene expression calls using RNA-seq data.

34. Shirakawa, H.

36. Hildebrandt, J. P. & Hildebrandt, P. Lysophosphatidic acid depletes intracellular calcium stores different from those mediating

40. Im, D. S. Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

41. Stoddard, N. C. & Chun, J. Promising pharmacological directions in the world of lysophosphatidic Acid signaling.
43. Cahalan, S. M. et al. Sphingosine 1-phosphate receptor 1 (SIP(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an SIP(1) antagonist. *Mol. Pharmacol.* **83**, 316–321, https://doi.org/10.1124/mol.112.082958 (2013).

44. Dubin, A. E., Bahnson, T., Weiner, J. A., Fukushima, N. & Chun, J. Lysosphatidic Acid Stimulates Neurotransmitter-Like Conductance Changes that Precede GABA and L-Glutamate in Early, Presumptive Cortical Neuroblasts. *J. Neurosci.* **19**, 1371–1381 (1999).

45. Ishikawa, J. et al. A Pyrazole Derivative, YM-58483, Potently Inhibits Store-Operated Sustained Ca2+ Influx and IL-2 Production in T Lymphocytes. *J. Immunol.* **170**, 4441–4449 (2003).

46. Zitt, C. et al. Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. *J. Biol. Chem.* **279**, 12427–12437, https://doi.org/10.1074/jbc.M309297200 (2004).

47. McGiffert, C., Contos, J. J., Friedman, B. & Chun, J. Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. *FEBS Lett.* **531**, 103–108 (2002).

48. Yung, Y. C., Stoddard, N. C., Mirendil, H. & Chun, J. Lysosphatidic Acid signaling in the nervous system. *Neuron* **85**, 669–682, https://doi.org/10.1016/j.neuron.2015.01.009 (2015).

49. Ryberg, E. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. *Br. J. Pharmacology* **152**, 1092–1101, https://doi.org/10.1038/sj.bjp.0707460 (2007).

50. Henstridge, C. M. et al. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. *FASEB journal: Off. Publ. Federation Am. Societies Exp. Biol.* **23**, 183–193, https://doi.org/10.1096/fj.08-108670 (2009).

Acknowledgements
The study was supported by a grant from l’Agence Nationale de la Recherche (ANR-16-CE29-0024 to AB). We also acknowledge support from the Centre National de la Recherche Scientifique (CNRS), the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), the Université de Grenoble Alpes (UGA), and the animal facility platform supported by GRAL, financed within the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). We wish to thank Drs C. Blugeon and S. Lemoine from the Institut de Biologie de l’Ecole Normale Supérieure (IBENS, Paris) for their help with the gene analysis. We also appreciate comments on this manuscript prior to submission from Dr J. Gibon (University of British Columbia, Kelowna). We also thank Dr A. Journet, E. Taillebourg and G. Courtois for reading the manuscript.

Author contributions
A.D., J.H. and A.B. performed experiments and analyzed data. A.B. designed the study and wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to A.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020